These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7527437)

  • 21. Alterations of gene expression in adult male rat testis and pituitary shortly after subacute administration of the antiandrogen flutamide.
    Ohsako S; Kubota K; Kurosawa S; Takeda K; Qing W; Ishimura R; Tohyama C
    J Reprod Dev; 2003 Aug; 49(4):275-90. PubMed ID: 14967920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma.
    Vollmer G; Michna H; Schneider MR
    Cancer Lett; 1996 Mar; 101(2):185-92. PubMed ID: 8620468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
    Gaillard-Moguilewsky M
    Urology; 1991; 37(2 Suppl):5-12. PubMed ID: 1992602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of chlormadinone acetate and its 3alpha- and 3beta-hydroxy metabolites on progesterone, androgen and glucocorticoid receptors.
    Schneider J; Kneip C; Jahnel U
    Pharmacology; 2009; 84(2):74-81. PubMed ID: 19590256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
    Moguilewsky M; Cotard M; Proulx L; Tournemine C; Raynaud JP
    Prog Clin Biol Res; 1987; 243A():315-40. PubMed ID: 3116549
    [No Abstract]   [Full Text] [Related]  

  • 28. Mechanism of androgen-induced thymolysis in rats.
    Kumar N; Shan LX; Hardy MP; Bardin CW; Sundaram K
    Endocrinology; 1995 Nov; 136(11):4887-93. PubMed ID: 7588221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate.
    Wilson MJ; Ludowese C; Sinha AA; Estensen RD
    Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of antiandrogen action: conformational changes of the receptor.
    Kuil CW; Mulder E
    Mol Cell Endocrinol; 1994 Jun; 102(1-2):R1-5. PubMed ID: 7926260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor progestagen, on the rat prostate.
    Botella J; Paris J; Lahlou B
    Acta Endocrinol (Copenh); 1987 Aug; 115(4):544-50. PubMed ID: 3630545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of antiandrogens and ethane dimethane sulphonate (EDS) on gene expression, free subunits, bioactivity and secretion of pituitary gonadotrophins in male rats.
    Gromoll J; Weinbauer GF; Simoni M; Nieschlag E
    Mol Cell Endocrinol; 1993 Feb; 91(1-2):119-25. PubMed ID: 8386109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the nuclear dihydrotestosterone receptor complex from rat ventral prostate by antiandrogens and stilboestrol.
    Smith CB; Ghanadian R; Chisholm GD
    Mol Cell Endocrinol; 1978; 10(1):13-20. PubMed ID: 75813
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiandrogen action in the development of androgen insensitivity in S115 mouse mammary tumour cells.
    Darbre PD; Chadwick J; Edwards H; Carrick N; Perachiotti A
    J Steroid Biochem Mol Biol; 1993 Sep; 46(3):299-307. PubMed ID: 9831478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
    Murakoshi M; Ikeda R; Fukui N; Nakayama T
    Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediation by an androgen receptor of the stimulatory effect of testosterone on the growth of a fibrosarcoma in the rat.
    Harraga A; Astre C; Possompes B; Saint Aubert B; Sultan C; Joyeux H
    Anticancer Res; 1995; 15(1):77-82. PubMed ID: 7733645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
    Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):961-5. PubMed ID: 11805337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.